TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07220811: Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,656,500

Rescue Site Savings

+$1,759,500

Unlock Full NCT07220811 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07220811 Rescue Dossier →